Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2110-2114

  Claret, Laurent ^a   Gupta, Manish ^b   Han, Kelong ^b   Joshi, Amita ^b   Sarapa, Nenad ^c   He, Jing ^d   Powell, Bob ^e   Bruno, René ^a  

^a Pharsight Consulting Services   (France)

^b GENENTECH INC   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Roche Product Development in Asia Pacific   (China)

^e Pharmaceutical Research and Early Development (PRED) Roche   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLACEBO; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; ETHNIC DIFFERENCE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; COLORECTAL NEOPLASMS; FEMALE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LONGITUDINAL STUDIES; MALE; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84887454644     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0973     Document Type: Article

References (20)

1. Claret L, Girard P, O’Shaughnessy J, et al: Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J Clin Oncol 24:307s, 2006 (suppl; abstr 6025)
2. Claret L, Girard P, Hoff PM, et al: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
3. Wang Y, Sung C, Dartois C, et al: Elucidation of relationship between tumor size and survival in non-small cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167-174, 2009
4. Claret L, Lu J-F, Sun Y-N, et al: Development of a modeling framework to simulate efficacy endpoints for motesanib in thyroid cancer patients. Cancer Chemother Pharmacol 66:1141-1149, 2010
5. Bruno R, Jonsson F, Zaki M, et al: Simulation of clinical outcome for pomalidomide plus low-dose dexamethasone in patients with refractory multiple myeloma based on week 8 M-protein response. Blood 118, 2011 (suppl; abstr 1881)
6. Claret L, Lu J, Bruno R, et al: Simulation of phase III studies of motesanib 125 mg once daily plus carboplatin/paclitaxel or bevacizumab plus carboplatin/paclitaxel versus carboplatin/paclitaxel in first-line non–small-cell lung cancer using a public domain drug-disease modeling framework and phase II data. J Clin Oncol 28, 2010 (suppl, abstr e18089)
7. Scagliotti G, Vynnychenko I, Ichinoseet Y, et al: An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). J Clin Oncol 30:2829-2836, 2011
8. Claret L, Lu J-F, Bruno R, et al: Simulations using a public domain drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer (NSCLC). Clin Pharmacol Ther 92:631-634, 2012
9. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
10. Lavin PT: An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451-457, 1981
11. Karrison TG, Maitland ML, Stadler WM, et al: Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007
12. Bruno R, Claret L: On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86:136-138, 2009
13. Maitland ML, Bies RR, Barrett JS: A time to keep and a time to cast away categories of tumor response. J Clin Oncol 29:3109-3111, 2011
14. Stein WD, Gulley JL, Schlom J, et al: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917, 2010
15. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
16. Guan ZZ, Xu JM, Luo RC, et al: Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized ARTIST phase III trial. Chinese J Cancer 30:682-689, 2011
17. Frances N, Claret L, Bruno R, et al: Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother Pharmacol 68:1413-1419, 2011
18. Beal SL, Sheiner LB: NONMEM Users Guides. San Francisco, CA, NONMEM Project Group, University of California at San Francisco, 1992
19. Akaike H: A new look at the statistical model identification. IEEE Transactions on Automatic Control 19:716-723, 1974
20. Sharma MR, Maitland ML, Ratain MJ: Models of excellence: Improving oncology drug development. Clin Pharmacol Ther 92:548-550, 2012